Evidence map›Paper›PMID 25423019›Full record

ArticleNature methods2014

Live-cell mass profiling: an emerging approach in quantitative biophysics.

Thomas A Zangle, Michael A Teitell

Abstract read
In one paragraph

Article in Nature methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Quantitative phase microscopies: accuracy comparison.Light, science & applications · 2024
    Review

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas A ZangleDepartment of Bioengineering, University of California, Los Angeles (UCLA), Los Angeles, California, USA.
Michael A Teitell1] Department of Bioengineering, University of California, Los Angeles (UCLA), Los Angeles, California, USA. [2] Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. [3] California NanoSystems Institute, UCLA, Los Angeles, California, USA. [4] Broad Stem Cell Research Center, UCLA, Los Angeles, California, USA. [5] Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA. [6] Molecular Biology Institute, UCLA, Los Angeles, California, USA.

Funding

UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
Human Embryonic Stem Cell CoreP01GM081621 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GALIC, ZORAN · 2008 to 2012
$9.3M
The Center for Systemic Control of Cyto-NetworksPN2EY018228 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HO, CHIH-MING · 2006 to 2010
$8.2M
RNA trafficking in mitochondriaR01GM073981 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Carla M Koehler, MICHAEL A TEITELL · 2006 to 2026
$5.1M
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIAR01CA090571 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2002 to 2015
$3.8M
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and PrognosisR01CA185189 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, JASON C, TEITELL, MICHAEL A · 2014 to 2017
$1.9M
A Fourth Outcome: DNA Damage and the Differentiation of B CellsR01CA156674 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2011 to 2015
$1.5M
A NOVEL MECHANISM OF TCL1 TUMORIGENESISR01CA107300 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2004 to 2008
$1.4M
Live Cell Interferometry for Quantifying Mass Transport in CancerK25CA157940 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZANGLE, THOMAS ANDREW · 2012 to 2014
$354k
NCI NIH HHS K25 CA157940NCI NIH HHS K25CA157940NCI NIH HHS R01 CA090571NCI NIH HHS R01 CA107300NCI NIH HHS R01 CA156674NCI NIH HHS R01CA156674NCI NIH HHS R01 CA185189NCI NIH HHS R01CA185189NCI NIH HHS R01CA90571NCI NIH HHS T32 CA009120NEI NIH HHS PN2 EY018228NEI NIH HHS PN2EY018228NIGMS NIH HHS P01 GM081621NIGMS NIH HHS P01GM081621NIGMS NIH HHS R01 GM073981NIGMS NIH HHS R01GM073981
6 · The paper itself

Abstract

Cell mass, volume and growth rate are tightly controlled biophysical parameters in cellular development and homeostasis, and pathological cell growth defines cancer in metazoans. The first measurements of cell mass were made in the 1950s, but only recently have advances in computer science and microfabrication spurred the rapid development of precision mass-quantifying approaches. Here we discuss available techniques for quantifying the mass of single live cells with an emphasis on relative features, capabilities and drawbacks for different applications.

Indexed as

Cell ProliferationCell SizeBiophysicsCell DifferentiationHumansInterferometry

Identifiers

PMID25423019
PMCPMC4319180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.